DODavid Olaleye

David Olaleye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Olaleye has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oral human papilloma virus infection among dental clinic attendees in Ibadan, Nigeria

    by Adedayo O. Faneye, Oyeteju S. Babalola, Georgina N. Odaibo, Juwon Arotiba, Olufemi D. Olaleye

    The African Journal of Laboratory Medicine focuses on the role of the laboratory and its professionals in the clinical and public healthcare sectors, and is specifically based on an African frame of reference.


  • Open Access

    Outbreak of Measles in vaccinated population in Southeastern Nigeria

    by J.A. Shenge, G.N. Odaibo, D.O. Olaleye

    Background: Outbreaks of respiratory disease, febrile illness and rash occurred in two adjoining rural communities of Imo State, Southeastern, Nigeria, at different times between 2006 and 2020. Laboratory investigation was carried out to determine the aetiological agent of the outbreak. Methodology: Oropharyngeal swabs were collected from 6 individuals showing symptoms of disease, within 3-4 days of appearance of rash. Venous blood samples were also collected from a total of 41 symptomatic persons, their contacts and individuals with resolved infections. Swabs were inoculated into Vero, HEp-2c, B95a and MDCK cell lines. Sera were analyzed using enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G and M to rubella and measles viruses, while immunofluorescence assay was used to detect Lassa fever virus immunoglobulins. Descriptive data were analyzed using the Statistical Package for the Social Sciences (SPSS). Results: Four of the 6 (66.7%) swab samples showed viral activity or cytopathic effect characterized by clumping of cells in Vero cells while 2 (33.3%) in Hep-2c characterized by rounding up of cells. Thirty-nine (95.1%) sera were positive for measles IgG while 13 (31.7%) were positive for IgM. Thirty-six (87.8%) sera were positive for rubella IgG but none was positive for IgM. None of the sera was positive for Lassa fever virus IgG and IgM. Conclusion: Measles virus was responsible for the outbreak among previously vaccinated population in the communities, while Rubella and Lassa fever viruses were excluded as the etiological agents of the outbreak. Keywords: Epidemics; IgG and IgM; Cell lines; Vaccination; Measles virus French title: Épidémie de rougeole dans la population vaccinée du sud-est du Nigéria Contexte: Des flambées de maladies respiratoires, de maladies fébriles et d'éruptions cutanées sont survenues dans deux communautés rurales voisines de l'État d'Imo, dans le sud-est du Nigéria, à des moments différents entre 2006 et 2020. Une enquête en laboratoire a été menée pour déterminer l'agent étiologique de l'épidémie. Méthodologie: Des écouvillons oropharyngés ont été prélevés sur 6 individus présentant des symptômes de maladie, dans les 3 à 4 jours suivant l'apparition de l'éruption cutanée. Des échantillons de sang veineux ont également été prélevés sur un total de 41 personnes symptomatiques, leurs contacts et des personnes souffrant d'infections résolues. Des écouvillons ont été inoculés dans des lignées cellulaires Vero, HEp-2c, B95a et MDCK. Les sérums ont été analysés en utilisant un test immuno-enzymatique (ELISA) pour les immunoglobulines G et M contre les virus de la rubéole et de la rougeole, tandis que le test d'immunofluorescence a été utilisé pour détecter les immunoglobulines du virus de la fièvre de Lassa. Les données descriptives ont été analysées à l'aide du progiciel statistique pour les sciences sociales (SPSS). Résultats: Quatre des 6 échantillons sur écouvillon (66,7%) ont montré une activité virale ou un effet cytopathique caractérisé par l'agglutination des cellules dans les cellules Vero, tandis que 2 (33,3%) dans Hep-2c étaient caractérisés par un arrondissement des cellules. Trente-neuf (95,1%) sérums étaient positifs pour les IgG contre la rougeole tandis que 13 (31,7%) étaient positifs pour les IgM. Trente-six (87,8%) sérums étaient positifs pour les IgG contre la rubéole, mais aucun n'était positif pour les IgM. Aucun des sérums n'était positif pour les IgG et IgM du virus de la fièvre de Lassa. Conclusion: Le virus de la rougeole était responsable de l'épidémie parmi la population précédemment vaccinée dans les communautés, tandis que les virus de la rubéole et de la fièvre de Lassa ont été exclus comme agents étiologiques de l'épidémie. Mots clés: épidémies; IgG et IgM; Lignées cellulaires; Vaccination; Virus de la rougeole


  • New infections and HIV‐1 subtypes among febrile persons and blood donors in Oyo State, Nigeria

    by Babatunde A. Olusola, David O. Olaleye, Georgina N. Odaibo

    Purpose: There were approximately 37.9 million persons infected with HIV in 2018 globally, resulting in 770,000 deaths annually. Over 50% of this infection and deaths occur in sub‐Saharan Africa, with countries like Nigeria being seriously affected. Nigeria has one of the highest rates of new infections globally. To control HIV infection in Nigeria, there is a need to continually screen high‐risk groups for early HIV infection and subtypes using very sensitive methods. In this study, new HIV‐1 infection and circulating HIV‐1 subtypes among febrile persons and blood donors were determined. Performance characteristics of three commercial EIA kits were also evaluated.Methods: In total, 1028 participants were recruited for the study. New HIV‐1 infection and subtypes were determined using enzyme immunoassays and molecular techniques, respectively. Sensitivity, specificity, predictive values, and agreements were compared among the EIA kits using PCR‐confirmed HIV‐positive and negative samples.Results: The overall prevalence of HIV infection in this study was 5.35%. The rate of new HIV infection was significantly different (p < .03674) among 1028 febrile persons (Ibadan: 2.22%; Saki: 1.36%) and blood donors (5.07%) studied. Three subtypes, CRF02_AG, A, and G, were found among those with new HIV infection. Whereas the commercial ELISA kits had very high specificities (94.12%, 100%, and 100%) for HIV‐1 detection, Alere Determine HIV‐1 antibody rapid kit had the lowest sensitivity score (50%).Conclusion: Genetic diversity of HIV‐1 strains among infected individuals in Oyo State, Nigeria, is still relatively high. This high level of diversity of HIV‐1 strains may impact the reliability of diagnosis of the virus in Nigeria and other African countries where many of the virus strains co‐circulate.


  • Open Access

    Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART

    by Holly E Rawizza, Regina Oladokun, Emeka Ejeliogu, Stephen Oguche, Babatunde O Ogunbosi, Oche Agbaji, Georgina Odaibo, Godwin Imade, David Olaleye, Lubbe Wiesner, et al.

    Treatment options are limited for TB/HIV-coinfected children who require PI-based ART. Rifabutin is the preferred rifamycin for adults on PIs, but the one study evaluating rifabutin with PIs among children was stopped early due to severe neutropenia. We evaluated rifabutin safety and plasma pharmacokinetics among coinfected children 3–15 years of age receiving rifabutin 2.5 mg/kg daily with standard doses of lopinavir/ritonavir. The AUC0–24 at 2, 4 and 8 weeks after rifabutin initiation was described using intensive sampling and non-compartmental analysis. Clinical and laboratory toxicities were intensively monitored at 12 visits throughout the study. Among 15 children with median (IQR) age 13.1 (10.9–14.0) years and weight 25.5 (22.3–30.5) kg, the median (IQR) rifabutin AUC0–24 was 5.21 (4.38–6.60) μg·h/mL. Four participants had AUC0–24 below 3.8 μg·h/mL (a target for the population average exposure) at week 2 and all had AUC0–24 higher than 3.8 μg·h/mL at the 4 and 8 week visits. Of 506 laboratory evaluations during rifabutin, grade 3 and grade 4 abnormalities occurred in 16 (3%) and 2 (0.4%) instances, respectively, involving 9 (60%) children. Specifically, grade 3 (n = 4) and grade 4 (n = 1) neutropenia resolved without treatment interruption or clinical sequelae in all patients. One child died at week 4 of HIV-related complications. In children, rifabutin 2.5 mg/kg daily achieved AUC0–24 comparable to adults and favourable HIV and TB treatment outcomes were observed. Severe neutropenia was relatively uncommon and improved with ongoing rifabutin therapy. These data support the use of rifabutin for TB/HIV-coinfected children who require lopinavir/ritonavir.


  • Open Access

    Enteric Adenovirus and Norovirus Gastroenteritis among Under-5 years Children in Owo, Ondo State, Nigeria

    by Michael Babalola, Georgina Odaibo, David Olaleye, Abel Alonge

    Aim: Infant mortality attributable to diarrhea continue unabated, without the precise determination of the viral etiologies. Few studies exist on enteric adenoviruses and norovirus infections in infants and young children in Nigeria. This study was aimed at the detection and determination of the baseline prevalence of enteric adenoviruses and norovirus pathogens among under -5 years children hospitalized for acute diarrhea in Ondo state, Nigeria. Methods: In a cross sectional descriptive study conducted between November 2013 and April 2014, fifty (50) fecal specimens collected from diarrheic children below 5 years and age matched non-diarrheic controls were screened for the presence of enteric adenovirus and norovirus antigens using a 4th generation quadruple Rapid Immuno- chromatographic Enzyme Immuno Assay kits. Results: Adenovirus antigen was detected in 9/50 (18%) in November 2013, and February to April 2014 while norovirus was found in 4/50 (8%) of the diarrheic children, in the months of December 2013 to February 2014. The prevalent age at infection were 0-6 months for adenovirus and 31-36 months for norovirus, while the male-to-female ratio was 1.8:1. Co-infection of adenovirus with rotavirus was detected in children between 7-12 months, while co-infection of adenovirus with norovirus was detected in children between 31-36 months old at a rate of 2% respectively. There was no significant difference in the induction of diarrhea in children by each of the two viruses (χ2=1.78), and no significant difference in the rate of adenovirus (χ2=0.605) and norovirus infections (χ2 =1.09) between male and female, in the study population. Conclusion: The baseline prevalence of enteric adenovirus diarrhea was 18% (occurring in November, February to April), norovirus was 8% (occurring in December to February), dual infection by adenovirus cum rotavirus, and adenovirus cum norovirus was 2% respectively, in children below 3 years in Ondo state Nigeria. The findings suggests that human enteric adenoviruses and norovirus are becoming established etiologies of infantile diarrhea in southwest Nigeria, and vaccines should be developed and vaccination implemented alongside rotavirus.


  • Open Access

    A new affordable flow cytometry based method to measure HIV‐1 viral load

    by Burkhard Greve, Jürgen Weidner, Uwe Cassens, Georgina Odaibo, David Olaleye, Walter Sibrowski, Doris Reichelt, Ines Nasdala, Wolfgang Göhde

    Most commercially available assays for diagnosis of HIV infection have shown shortcomings in the detection and quantification of rare genotypes of the virus. Most of the assays do not detect subtype O (outlier) and/or N (nonmajor, nonoutlier) or new circulating recombinant forms (CRFs), which are becoming more important in sub‐Saharan Africa. Furthermore, the commonly available tests require costly measuring devices and expensive test kits, which are not easily affordable for developing countries. This study was designed to explore solutions to the problem of viral load assays in developing countries. Two forward primers, digoxygenin (DIG) and dinitrophenol (DNP) labeled, and one biotin (BIO) labeled reverse primer were used to amplify both, the HIV‐1‐5′LTR (long terminal repeat) region and an internal standard sequence. The two polymerase chain reaction (PCR)‐products were captured by anti‐DIG and anti‐DNP antibody coated microparticles. Flow cytometric analyses were carried out after labeling with streptavidin‐R‐phycoerythrine. The primer system used recognized all HIV‐1 subtypes. A coamplified internal standard warranted the functionality of the PCR and allows reproducible viral load measurements. Two drawbacks of current viral load measurements are overcome by the flow cytometry based test described hereof. First, all known worldwide relevant HIV‐1 subtypes including subtypes O, N, and new CRFs are quantifiable with high sensitivity (50 to >1 × 106 copies per PCR). Second, the cost per test can be reduced to less than 12 US$ instead of the current 50–100 US$. Additionally, the test described in this report offers the possibility to perform complete monitoring program (CD4 T‐cell count, CD4% and viral load) for the first time, with the same device for HIV‐infected persons. © 2008 International Society for Advancement of Cytometry